Drug Trial Radar · NCT07287098
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
Jan 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days. Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.
Conditions
- Breast Neoplasms
Interventions
ImlunestrantDrug
Given orally
GoserelinDrug
Given SC
Tamoxifen 20 mgDrug
Given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Antigen Kiel (Ki-67) ExpressionTime frame: Baseline, Day 29
- Rate of Symptomatic Ovarian CystsTime frame: Up to Day 180
Locations
90 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Not yet recruiting
Ironwood Cancer & Research Centers
Chandler, Arizona · Not yet recruiting
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona · Not yet recruiting
City of Hope, Phoenix
Phoenix, Arizona · Not yet recruiting
City of Hope
Duarte, California · Not yet recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Not yet recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Hematology/Oncology - Parkside
Santa Monica, California · Not yet recruiting
Banner MD Anderson Cancer Center at North Colorado Medical Center
Greeley, Colorado · Recruiting
Banner MD Anderson Cancer Center at McKee Medical Center
Loveland, Colorado · Recruiting
AdventHealth Altamonte Springs
Altamonte Springs, Florida · Not yet recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Not yet recruiting
Winship Cancer Institute
Atlanta, Georgia · Not yet recruiting
City of Hope National Medical Center, Atlanta Cancer Center
Newnan, Georgia · Not yet recruiting
City of Hope, Chicago
Chicago, Illinois · Not yet recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Recruiting
University of Kentucky Chandler Medical Center
Lexington, Kentucky · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Not yet recruiting
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota · Not yet recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Wilmot Cancer Institute
Rochester, New York · Not yet recruiting
New York Cancer and Blood Specialists
Shirley, New York · Recruiting
University of North Carolina Medical Center
Chapel Hill, North Carolina · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Suspended
Providence Portland Medical Center
Portland, Oregon · Recruiting
Providence St. Vincent Medical Center
Portland, Oregon · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Houston Methodist Hospital
Houston, Texas · Not yet recruiting
Oncology Consultants P.A.
Houston, Texas · Recruiting
Baylor Scott & White Medical Center - Round Rock
Round Rock, Texas · Not yet recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Not yet recruiting
The University of Vermont Medical Center Inc.
Burlington, Vermont · Not yet recruiting
University of Virginia Health System
Charlottesville, Virginia · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Cliniques universitaires Saint-Luc
Brussels, Belgium · Not yet recruiting
Antwerp University Hospital
Edegem, Belgium · Not yet recruiting
UZ Leuven
Leuven, Belgium · Not yet recruiting
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.